TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12690054
Drug: L-dopa, STN
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa, STN stimulation, and combined treatment
Study: 1736456
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Study: 1774568
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices (SCD)
Study: 24529603
Drug: Multi-convergent therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-convergent therapy (MCT) for 16 weeks
Study: 22378825
Drug: Fetal ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fetal ethanol exposure (administered to dams through a liquid diet)
Study: 20470336
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg x kg(‐1) in 5 ml of honey)
Study: 20470336
Drug: Midazolam-Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-Ketamine (0.25 mg x kg(‐1) midazolam mixed with 1 mg x kg(‐1) ketamine in 5-ml honey)
Study: 20470336
Drug: Placebo (5-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5-ml honey alone)
Study: 18257184
Drug: L-Dopa (Control)
Normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-Dopa (Control)
Study: 16416346
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment for hypothyroidism
Study: 12801161
Drug: Sertraline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline at a dosage of 200 mg/day during the 8-week open-label extension phase.
Study: 12801161
Drug: Sertraline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline at a dosage of 100 mg/day during the acute phase.
Study: 10929571
Drug: bupropion-SR 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion-SR 150 mg/day
Study: 10929571
Drug: bupropion-SR 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion-SR 300 mg/day
Study: 8842507
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (2 mg/kg iv over 10 minutes followed by 0.007 mg/kg/min)
Study: 8842507
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (0.9% saline solution)
Study: 7484039
Drug: esmolol 2
Normalized name: esmolol 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 2 mg.kg‐1
Study: 788993
Drug: Aspirin 1200
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1200 mg
Study: 12799117
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil formulation dentifrice
Study: 1735697
Drug: AK-2123 (3-nitro-1,2,4-triazole)
Normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AK-2123 (3-nitro-1,2,4-triazole) intratumoral injection at 1% and 2%
Study: 1735697
Drug: AK-2123 (3-nitro-1,2,4-triazole)
Normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AK-2123 (3-nitro-1,2,4-triazole) intratumoral injection
Study: 6365350
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg orally every 4 hr for 14 days)
Study: 30103622
Drug: Patiromer (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (8.4 g/d to start, adjusted to maintain serum potassium of 3.8 to 5.0 mEq/L)
Study: 20210620
Drug: gel jacket
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel jacket
Study: 18538692
Drug: Anti-NB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-NB treatment
Study: 16006454
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day acarbose
Study: 10049281
Drug: Stavudine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (40 mg twice daily) in combination with one to three other drugs for opportunistic infections
Study: 10049281
Drug: Stavudine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (40 mg twice daily)
Study: 8657058
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, then 100 mg daily for 13 days)
Study: 8657058
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same parodontal therapy without doxycycline)
Study: 348309
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CY), 60 mg/kg iv, given on Days 1 and 2
Study: 348309
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CY), 60 mg/kg iv, given on Days 1 and 8
Study: 348309
Drug: COMB (CY,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMB (CY, 800 mg/m2; vincristine [Oncovin], 1.4 mg/m2; methotrexate, 20 mg/m2; and BCNU, 60 mg/m2)
Study: 11107508
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of dipyridamole (0.5 mg/kg body weight)
Study: 9236429
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of Ang II
Study: 29485790
Drug: Paracetamol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol administered through patient-controlled analgesia (PCA) pump
Study: 29485790
Drug: Paracetamol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol administered intermittently
Study: 25344090
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg AA
Study: 25344090
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg AA
Study: 25344090
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg AA
Study: 25344090
Drug: 1 hour
Normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hour premeal 1000 mg AA
Study: 25344090
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours postmeal 1000 mg AA
Study: 25344090
Drug: 4 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 hours apart meals 1000 mg AA
Study: 19144392
Drug: NovaSil clay
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovaSil clay (high dose)
Study: 19144392
Drug: NovaSil clay
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovaSil clay (low dose)
Study: 14709460
Drug: Continuous three‐in‐one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous three‐in‐one femoral nerve block (FEM) with 30 mL ropivacaine 0.5% and epinephrine 1:200,000 bolus followed by an infusion of ropivacaine 0.2% at 12 mL/hr for 48 hr
Study: 14709460
Drug: Continuous posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous posterior lumbar plexus (PSOAS) block with the same bolus and infusion regimen as the FEM group
Study: 14709460
Drug: iv patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv patient‐controlled morphine analgesia (PCA)
Study: 11826911
Drug: Loratadine syrup
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine syrup 5 mg or 10 mg daily for 3 weeks
Study: 8956350
Drug: l-methadone (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-methadone (n = 13)
Study: 29972633
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg with Cyclosporine 100 mg
Study: 29972633
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg with Tacrolimus 5 mg
Study: 26760084
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment (higher-dose rifampin 15 mg/kg/day and levofloxacin 20 mg/kg/day for the first 8 weeks)
Study: 26760084
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (10 mg rifampin/kg/day for 9 months)
Study: 22554203
Drug: Artemisinin-naphthoquine (AN)
Normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-naphthoquine (AN) - single dose of four tablets on day 0
Study: 22554203
Drug: Dihydroartemisinin-piperaquine (DHP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DHP) - three to four tablets daily for three days
Study: 19088171
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Study: 19088171
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Study: 19088171
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg + pemetrexed
Study: 19088171
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg + pemetrexed
Study: 16449845
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nicotinic acid and Bezafibrate
Study: 12133363
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) in group B(1), n = 20
Study: 9818786
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg picotamide daily
Study: 6107116
Drug: Clobazam 10
Normalized name: cloBAZam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 10 mg three times daily
Study: 35211
Drug: Chlordiazepoxide 10
Normalized name: chlordiazepoxide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide 10 mg three times daily
Study: 28403662
Drug: Soluble intercellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble intercellular adhesion molecule 1 (sICAM‐1)
Study: 28403662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CPIS and SAA
Study: 27632342
Drug: Hydrogel spacer
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel spacer injection before RT
Study: 26402319
Drug: Combination sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination sedation (repeated bolus doses of fentanyl with propofol infusion)
Study: 26402319
Drug: Conventional sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sedation (initial bolus of meperidine with propofol infusion)
Study: 26402319
Drug: Combination sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination sedation
Study: 15497670
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (30 mg pioglitazone hydrochloride)
Study: 15497670
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (30 mg pioglitazone hydrochloride)
Study: 15497670
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation and Reference formulation
Study: 9466097
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections pre- and intra-operatively (Group A)
Study: 9466097
Drug: Placebo pre-operatively
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo pre-operatively and ketorolac 30 mg intra-operatively (Group B)
Study: 9466097
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg pre-operatively and ketorolac 20 mg intra-operatively (Group C)
Study: 9466097
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg pre-operatively and placebo intra-operatively (Group D)
Study: 7887164
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution 5% applied prior to preoperative wash of the fornices with normal saline.
Study: 2895319
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (59 patients)
Study: 12366728
Drug: Topiramate 200
Normalized name: topiramate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 200 mg
Study: 25433970
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by male operators to female subjects
Study: 25433970
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by female operators to male subjects
Study: 25433970
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by male operators to male subjects
Study: 25433970
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by female operators to female subjects
Study: 18628449
Drug: Multi-arm experimental
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-arm experimental treatments
Study: 12973834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - 2 cycles
Study: 12973834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - 1 cycle
Study: 8710750
Drug: Cetylpyridinium chloride
Normalized name: Cetylpyridinium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetylpyridinium chloride in candy based lozenges
Study: 8710750
Drug: Aqueous solutions
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solutions of the lozenges
Study: 1711614
Drug: Bendrofluazide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (10 mg/day)
Study: 6354023
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (18 mg nebulized)
Study: 6354023
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate (3 mg nebulized)
Study: 6354023
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate (18 mg nebulized)
Study: 27773851
Drug: Intradermal allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal allergen injections (7 ng of Phl p 5 major allergen)
Study: 27513252
Drug: Propofol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.75 mg/kg iv)
Study: 24290345
Drug: Oligofructose/inulin 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose/inulin 7 g/d
Study: 22122999
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin only once daily
Study: 22122999
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin + 20 mg famotidine twice daily
Study: 22122999
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rabeprazole once daily
Study: 17395869
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (balloon angioplasty or stenting)
Study: 15802975
Drug: High ddI
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ddI doses or taking a third NA
Study: 11867504
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) 2 x 600 mg oral tablets
Study: 10464891
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 800 micrograms per day
Study: 8557242
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue (B28Asp)
Study: 31006728
Drug: Ethyl icosapentate
Normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ethyl icosapentate (EPA) 1.8 g t.i.d.
Study: 31006728
Drug: EPA+DHA 2
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA 2 g s.i.d.
Study: 26281201
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment and azathioprine 2 mg/kg/day
Study: 26281201
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day
Study: 23794338
Drug: Azithromycin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, amoxicillin, and omeprazole
Study: 23794338
Drug: Clarithromycin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Study: 23794338
Drug: Azithromycin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Study: 21784839
Drug: ARB (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (100 mg/d losartan)
Study: 21784839
Drug: ARB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide)
Study: 10954001
Drug: Aspirin D,L-lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin D,L-lysine (18 mg/kg)
Study: 8243524
Drug: Pentaglobin (IgM-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (IgM-enriched intravenous immunoglobulin)
Study: 30095659
Drug: Prophylactic infusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusion of phenylephrine
Study: 27751846
Drug: Regorafenib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (160 mg per day, 3 weeks on and 1 week off)
Study: 22397215
Drug: Sodium enoxaparin
Normalized name: Enoxaparin Sodium
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium enoxaparin treatment for 10 days, followed by an additional 10 days after a 10-day no treatment period.
Study: 20546462
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus oral iron (single intravenous iron polymaltose infusion + daily oral ferrous sulphate 250 mg)
Study: 20546462
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron only (daily oral ferrous sulphate 250 mg)
Study: 20546462
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus oral iron
Study: 20546462
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron only
Study: 18192624
Drug: After-school treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After-school treatment program (10-week duration)
Study: 11759825
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg/day
Study: 11759825
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg/every other day
Study: 7827298
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation
Study: 2962597
Drug: CT with
Normalized name: Impact with Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT with intravenous contrast enhancement
Study: 31707860
Drug: SNF472 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNF472 300 mg
Study: 31707860
Drug: SNF472 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNF472 600 mg
Study: 24824633
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg three times a day
Study: 23328996
Drug: Docetaxel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (30 mg/m²) and cisplatin (30 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Study: 23328996
Drug: Single-agent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent cisplatin (40 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Study: 8630937
Drug: 5‐FU infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU infusions plus oral HCFU administration (Group A)
Study: 8630937
Drug: 5‐FU injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU injections (Group B)
Study: 1558344
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (325 mg aspirin, 75 mg dipyridamole, starting 12 hours preoperatively and continuing for 1 year)
Study: 1558344
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication identical in appearance to the study drugs
Study: 2859043
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg propranolol LA
Study: 29855153
Drug: Dexamethasone (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.7 mg implant)
Study: 22698597
Drug: Tricuspid regurgitation
Normalized name: Maclura tricuspidata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricuspid regurgitation treatment (group T)
Study: 22698597
Drug: No tricuspid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tricuspid regurgitation treatment (group no-T)
Study: 22698597
Drug: Tricuspid regurgitation
Normalized name: Maclura tricuspidata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricuspid regurgitation treatment (group T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Study: 22698597
Drug: No tricuspid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tricuspid regurgitation treatment (group no-T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Study: 22698597
Drug: No tricuspid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tricuspid regurgitation treatment (group no-T) in subgroup B (TAD/BSA > 21 mm/m2)